A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry-Reference-Cited by-同舟云学术

A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry

Published:2016-03 Issue: Volume:1015-1016 Page:42-49
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Yoneyama Tomoki^ORCID,Teshima Koichiro,Jinno Fumihiro,Kondo Takahiro,Asahi Satoru

Funder

Pharmaceutical Development Division of Takeda Pharmaceutical Company Limited for conducting and providing the PK data of the clinical study

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference18 articles.

1. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB);Arikawa;J. Med. Chem.,2012

2. High-throughput screening of potassium-competitive acid blockers;Kondo;J. Biomol. Screen.,2012

3. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers;Nishida;Bioorg. Med. Chem.,2012

4. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases;Hori;J. Pharmacol. Exp. Ther.,2010

5. A study comparing the antisecretory effect of TAK-438 a novel potassium-competitive acid blocker, with lansoprazole in animals;Hori;J. Pharmacol. Exp. Ther.,2011

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factorial design-aided derivatization-free fluorimetric ultrasensitive assay of vonoprazan with application in uniformity of dosage units and plasma samples analysis: Comprehensive and comparative greenness and whiteness assessment;Microchemical Journal;2024-10

2. Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders;Drug Metabolism and Pharmacokinetics;2024-07

3. Validated chromatographic approach for determination of two ternary mixtures in newly approved formulations for helicobacter pylori eradication: assessment of greenness profile and content uniformity;BMC Chemistry;2024-06-12

4. A comparative analysis of univariate versus multivariate eco-friendly spectrophotometric manipulations for resolving severely overlapped spectra of vonoprazan and amoxicillin new combination;Analytical Biochemistry;2024-06

5. An eco-friendly liquid chromatographic analysis of the triple therapy protocol of amoxicillin, metronidazole and vonoprazan for H. Pylori eradication: application to combined dosage forms and simulated gastric fluid;BMC Chemistry;2024-05-30